Apnimed's $192M IPO Backs First Oral OSA Drug Ahead of FDA Decision

References

1. 1.Vinluan, F. (2026, August 2). Apnimed's IPO bags $192M for what could become the first oral sleep apnea drug. MedCity News. https://medcitynews.com/2026/08/apnimed-ipo-apmd-obstructive-sleep-apnea-osa-oxnimbi-atomoxetine-aroxybutynin/
2. 2.Taranto-Montemurro, L., Messineo, L., Sands, S. A., Azarbarzin, A., Marques, M., Edwards, B. A., Eckert, D. J., White, D. P., & Wellman, A. (2019). The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity: A randomized, placebo-controlled, double-blind crossover trial. American Journal of Respiratory and Critical Care Medicine, 199(10), 1267–1276. https://doi.org/10.1164/rccm.201808-1493OC
3. 3.Benjafield, A. V., Ayas, N. T., Eastwood, P. R., Heinzer, R., Ip, M. S. M., Morrell, M. J., Nunez, C. M., Patel, S. R., Penzel, T., Pépin, J.-L., Peppard, P. E., Sinha, S., Tufik, S., Valentine, K., & Malhotra, A. (2019). Estimation of the global prevalence and burden of obstructive sleep apnoea: A literature-based analysis. The Lancet Respiratory Medicine, 7(8), 687–698. https://doi.org/10.1016/S2213-2600(19)30198-5
4. 4.Rotenberg, B. W., Murariu, D., & Pang, K. P. (2016). Trends in CPAP adherence over twenty years of data collection: A flattened curve. Journal of Otolaryngology — Head & Neck Surgery, 45(1), 43. https://doi.org/10.1186/s40463-016-0156-0
5. 5.Strollo, P. J., Soose, R. J., Maurer, J. T., de Vries, N., Cornelius, J., Froymovich, O., Hanson, R. D., Padhya, T. A., Steward, D. L., Gillespie, M. B., Woodson, B. T., Van de Heyning, P. H., Goetting, M. G., Vanderveken, O. M., Feldman, N., Knaack, L., & Strohl, K. P. (2014). Upper-airway stimulation for obstructive sleep apnea. New England Journal of Medicine, 370(2), 139–149. https://doi.org/10.1056/NEJMoa1308659
6. 6.Gottlieb, D. J., & Punjabi, N. M. (2020). Diagnosis and management of obstructive sleep apnea: A review. JAMA, 323(14), 1389–1400. https://doi.org/10.1001/jama.2020.3514
7. 7.US Food and Drug Administration. (2011). Strattera (atomoxetine): Drug safety communication — revised warnings about suicidal thinking and behavior. FDA Drug Safety Communications. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-warnings-about-suicidal-thinking-and-behavior-children-and
8. 8.Kaambwa, B., Ratcliffe, J., Horsfall, M., Mpundu-Kaambwa, C., & Eckert, D. J. (2022). Cost-effectiveness of treatments for obstructive sleep apnoea: A systematic review of economic evaluations. PharmacoEconomics, 40(3), 271–292. https://doi.org/10.1007/s40273-021-01118-6